MA42828A - Plate-forme d'échafaudage à noeud de cystine - Google Patents

Plate-forme d'échafaudage à noeud de cystine

Info

Publication number: MA42828A
Authority: MA; Morocco
Prior art keywords: cystine knot; scaffolding platform; scaffolding; platform; cystine
Prior art date: 2015-09-15

Application number

MA042828A

Other languages

English (en)

Inventor

Xinxin Gao

Rami Hannoush

Harini Kaluarachchi

Aaron NILE

Cameron Noland

Yingnan Zhang

Lijuan Zhou

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-15

Filing date

2016-09-15

Publication date

2018-07-25

2016-09-15 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2018-07-25 Publication of MA42828A publication Critical patent/MA42828A/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/63—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from plants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Ophthalmology & Optometry (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Botany (AREA)
Immunology (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Materials For Medical Uses (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

MA042828A 2015-09-15 2016-09-15 Plate-forme d'échafaudage à noeud de cystine MA42828A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562219063P	2015-09-15	2015-09-15

Publications (1)

Publication Number	Publication Date
MA42828A true MA42828A (fr)	2018-07-25

Family

ID=57068206

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA042828A MA42828A (fr)	2015-09-15	2016-09-15	Plate-forme d'échafaudage à noeud de cystine

Country Status (23)

Country	Link
US (8)	US10428125B2 (fr)
EP (1)	EP3350215A1 (fr)
JP (2)	JP7166916B2 (fr)
KR (1)	KR20180052718A (fr)
CN (3)	CN114805528A (fr)
AR (1)	AR106032A1 (fr)
AU (2)	AU2016323445B2 (fr)
BR (1)	BR112018002263A2 (fr)
CA (1)	CA2996006A1 (fr)
CL (2)	CL2018000668A1 (fr)
CO (1)	CO2018002510A2 (fr)
CR (1)	CR20180169A (fr)
HK (1)	HK1253318A1 (fr)
IL (2)	IL257399B (fr)
MA (1)	MA42828A (fr)
MX (1)	MX2018002922A (fr)
MY (1)	MY190552A (fr)
PE (1)	PE20181293A1 (fr)
PH (1)	PH12018500577A1 (fr)
RU (1)	RU2770384C2 (fr)
TW (1)	TWI799366B (fr)
UA (1)	UA125505C2 (fr)
WO (1)	WO2017049009A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI799366B (zh)	2015-09-15	2023-04-21	美商建南德克公司	胱胺酸結骨架平臺
WO2019233605A1 (fr) *	2018-06-08	2019-12-12	BioNTech SE	Compositions et méthodes pour le diagnostic et le traitement du cancer
MX2022015651A (es)	2020-06-11	2023-01-16	Genentech Inc	Conjugados de nanolipoproteina-polipeptido y composiciones, sistemas y procedimientos mediante el uso de los mismos.

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US918814A (en)	1907-10-30	1909-04-20	Handy Mfg Company	Funnel.
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4666884A (en)	1984-04-10	1987-05-19	New England Deaconess Hospital	Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
EP0206448B1 (fr)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US5225538A (en)	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
WO1991014438A1 (fr)	1990-03-20	1991-10-03	The Trustees Of Columbia University In The City Of New York	Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante
PT752248E (pt)	1992-11-13	2001-01-31	Idec Pharma Corp	Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5834252A (en)	1995-04-18	1998-11-10	Glaxo Group Limited	End-complementary polymerase reaction
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en)	1995-04-14	1998-05-05	Genentech, Inc.	Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
WO1997043316A1 (fr)	1996-05-10	1997-11-20	Beth Israel Deaconess Medical Center, Inc.	Molecules physiologiquement actives a demi-vies prolongees et methode d'utilisation de ces dernieres
PL199659B1 (pl)	1998-02-25	2008-10-31	Merck Patent Gmbh	Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
US20020142374A1 (en)	1998-08-17	2002-10-03	Michael Gallo	Generation of modified molecules with increased serum half-lives
EP1268544A2 (fr)	2000-03-31	2003-01-02	Institut Pasteur	Peptides inhibant l'angiogenese induite par le vegf (facteur de croissance endotheliale), polynucleotides codant pour ces peptides et leurs procedes d'utilisation
AU2001265198A1 (en)	2000-06-01	2001-12-11	Amgen Inc.	Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
DE60143544D1 (de)	2000-12-12	2011-01-05	Medimmune Llc	Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US7883717B2 (en)	2001-06-12	2011-02-08	Johns Hopkins University	Reservoir device for intraocular drug delivery
AU2002340080A1 (en)	2001-10-03	2003-04-14	Regeneron Pharmaceuticals, Inc.	Anti-angiogenic peptides
GB0130738D0 (en)	2001-12-21	2002-02-06	Serono Internat S A	Protein
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
WO2005110374A1 (fr)	2004-04-30	2005-11-24	Allergan, Inc.	Systemes de distribution de medicaments intraoculaires contenant un agent therapeutique, une cyclodextrine et un composant polymere
US20060182783A1 (en)	2004-04-30	2006-08-17	Allergan, Inc.	Sustained release intraocular drug delivery systems
DE102005002978B4 (de)	2005-01-21	2013-04-25	Merz Pharma Gmbh & Co. Kgaa	Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
US7863239B2 (en)	2005-01-24	2011-01-04	Pepscan Systems B.V.	Binding compounds, immunogenic compounds and peptidomimetics
US20060204548A1 (en)	2005-03-01	2006-09-14	Allergan, Inc.	Microimplants for ocular administration
US20090305994A1 (en)	2005-06-29	2009-12-10	D Andrea Lucas Domenico	Compounds Modulating Vegf Receptor and Uses Thereof
CN101583370A (zh) *	2005-09-27	2009-11-18	阿穆尼克斯公司	蛋白质药物及其用途
US20070191272A1 (en)	2005-09-27	2007-08-16	Stemmer Willem P	Proteinaceous pharmaceuticals and uses thereof
TW200732347A (en)	2005-10-06	2007-09-01	Trophogen Inc	VEGF analogs and methods of use
US7918814B2 (en)	2006-05-02	2011-04-05	Georgia Tech Research Corporation	Method for drug delivery to ocular tissue using microneedle
WO2008045252A2 (fr)	2006-10-04	2008-04-17	The Board Of Trustees Of The Leland Stanford Junior University	Peptides modifies de liaison aux integrines
US8039010B2 (en)	2006-11-03	2011-10-18	Allergan, Inc.	Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
CA2670990A1 (fr)	2006-12-01	2008-06-12	Allergan, Inc.	Procede pour determiner des emplacements oculaires optimaux pour des systemes d'administration de medicament
CN101835492B (zh)	2007-08-21	2012-11-21	德克萨斯州立大学董事会	用于制药应用的热动力学混合
AU2009228158B2 (en)	2008-03-27	2014-02-27	Zymogenetics, Inc.	Compositions and methods for inhibiting PDGFRbeta and VEGF-A
US8557273B2 (en)	2008-04-18	2013-10-15	Medtronic, Inc.	Medical devices and methods including polymers having biologically active agents therein
US8821870B2 (en)	2008-07-18	2014-09-02	Allergan, Inc.	Method for treating atrophic age related macular degeneration
EP2349327A4 (fr) *	2008-10-23	2012-11-28	Massachusetts Inst Technology	Engagement dirigé de récepteurs fc activateurs
DK2358746T3 (da)	2008-11-03	2020-12-21	Molecular Partners Ag	Bindingsproteiner til inhibering af vegf-a-receptorinteraktionen
EP2391419B1 (fr)	2009-01-29	2019-06-12	ForSight Vision4, Inc.	Administration d'un médicament dans le segment postérieur
US8778888B2 (en)	2009-11-06	2014-07-15	The Board Of Trustees Of The Leland Stanford Junior University	Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
US20110207653A1 (en)	2009-12-21	2011-08-25	Adrian Raiche	Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent
WO2011079232A1 (fr)	2009-12-23	2011-06-30	Psivida Us, Inc.	Dispositifs d'administration à libération prolongée
US8339139B2 (en) *	2010-01-29	2012-12-25	Infineon Technologies Ag	System and method for testing a circuit
CA2817197C (fr)	2010-11-08	2020-08-04	The Board Of Trustees Of The Leland Stanford Junior University	Proteines de fusion comprenant un peptide knottine modifie et utilisations de celles-ci
EP3363437B8 (fr) *	2011-02-18	2021-11-03	Endo Pharmaceuticals Inc.	Composés d'aminoindane et leur utilisation dans le traitement de la douleur
US9187553B2 (en)	2012-01-25	2015-11-17	Swey-Shen Chen	Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
JP2015528454A (ja) *	2012-08-28	2015-09-28	ノバルティスアーゲー	眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用
GB201218278D0 (en) *	2012-10-11	2012-11-28	Cyclogenix Ltd	Translocating peptide
TWI799366B (zh) *	2015-09-15	2023-04-21	美商建南德克公司	胱胺酸結骨架平臺

2016
- 2016-09-14 TW TW105130077A patent/TWI799366B/zh active
- 2016-09-15 IL IL257399A patent/IL257399B/en unknown
- 2016-09-15 CA CA2996006A patent/CA2996006A1/fr active Pending
- 2016-09-15 CN CN202210278014.4A patent/CN114805528A/zh active Pending
- 2016-09-15 BR BR112018002263A patent/BR112018002263A2/pt active Search and Examination
- 2016-09-15 AR ARP160102810A patent/AR106032A1/es unknown
- 2016-09-15 AU AU2016323445A patent/AU2016323445B2/en active Active
- 2016-09-15 CN CN201680052527.6A patent/CN108026162B/zh active Active
- 2016-09-15 CN CN202210278625.9A patent/CN114591422A/zh active Pending
- 2016-09-15 PE PE2018000390A patent/PE20181293A1/es unknown
- 2016-09-15 RU RU2018113442A patent/RU2770384C2/ru active
- 2016-09-15 EP EP16775922.4A patent/EP3350215A1/fr active Pending
- 2016-09-15 CR CR20180169A patent/CR20180169A/es unknown
- 2016-09-15 MY MYPI2018000374A patent/MY190552A/en unknown
- 2016-09-15 WO PCT/US2016/052012 patent/WO2017049009A1/fr active Application Filing
- 2016-09-15 MX MX2018002922A patent/MX2018002922A/es unknown
- 2016-09-15 MA MA042828A patent/MA42828A/fr unknown
- 2016-09-15 US US15/267,087 patent/US10428125B2/en active Active
- 2016-09-15 IL IL294568A patent/IL294568A/en unknown
- 2016-09-15 KR KR1020187010195A patent/KR20180052718A/ko not_active Application Discontinuation
- 2016-09-15 JP JP2018513360A patent/JP7166916B2/ja active Active
- 2016-09-15 UA UAA201804058A patent/UA125505C2/uk unknown
2018
- 2018-03-07 CO CONC2018/0002510A patent/CO2018002510A2/es unknown
- 2018-03-13 CL CL2018000668A patent/CL2018000668A1/es unknown
- 2018-03-15 PH PH12018500577A patent/PH12018500577A1/en unknown
- 2018-04-03 US US15/944,700 patent/US10696721B2/en active Active
- 2018-10-02 HK HK18112611.4A patent/HK1253318A1/zh unknown
2019
- 2019-08-19 US US16/544,394 patent/US11407794B2/en active Active
- 2019-09-18 US US16/574,917 patent/US11155586B2/en active Active
- 2019-09-18 US US16/574,910 patent/US11078243B2/en active Active
2020
- 2020-06-29 US US16/915,387 patent/US20200325187A1/en not_active Abandoned
- 2020-07-02 CL CL2020001781A patent/CL2020001781A1/es unknown
2021
- 2021-06-28 AU AU2021204400A patent/AU2021204400B2/en active Active
2022
- 2022-06-15 JP JP2022096301A patent/JP2022130481A/ja active Pending
- 2022-06-17 US US17/843,595 patent/US20230174596A1/en not_active Abandoned
2023
- 2023-10-30 US US18/497,741 patent/US20240247034A1/en active Pending

Also Published As

Publication number	Publication date
UA125505C2 (uk)	2022-04-13
US10428125B2 (en)	2019-10-01
RU2018113442A3 (fr)	2020-02-17
CA2996006A1 (fr)	2017-03-23
HK1253318A1 (zh)	2019-06-14
BR112018002263A2 (pt)	2018-09-18
CR20180169A (es)	2018-04-24
JP7166916B2 (ja)	2022-11-08
AU2021204400A1 (en)	2021-07-22
AU2016323445A1 (en)	2018-03-01
PE20181293A1 (es)	2018-08-07
US20200231636A1 (en)	2020-07-23
CN114805528A (zh)	2022-07-29
US20200140498A1 (en)	2020-05-07
RU2770384C2 (ru)	2022-04-15
US20170129927A1 (en)	2017-05-11
IL294568A (en)	2022-09-01
CN108026162A (zh)	2018-05-11
KR20180052718A (ko)	2018-05-18
US11078243B2 (en)	2021-08-03
US10696721B2 (en)	2020-06-30
IL257399A (en)	2018-04-30
PH12018500577A1 (en)	2018-10-15
TW201717993A (zh)	2017-06-01
CN108026162B (zh)	2022-04-05
US20200115424A1 (en)	2020-04-16
RU2018113442A (ru)	2019-10-16
CL2018000668A1 (es)	2018-07-20
TWI799366B (zh)	2023-04-21
MX2018002922A (es)	2018-06-07
CL2020001781A1 (es)	2020-10-23
JP2022130481A (ja)	2022-09-06
AR106032A1 (es)	2017-12-06
IL257399B (en)	2022-08-01
US20230174596A1 (en)	2023-06-08
WO2017049009A1 (fr)	2017-03-23
AU2021204400B2 (en)	2023-02-02
US20200325187A1 (en)	2020-10-15
JP2018533912A (ja)	2018-11-22
AU2016323445B2 (en)	2021-04-01
MY190552A (en)	2022-04-27
CO2018002510A2 (es)	2018-05-31
US20240247034A1 (en)	2024-07-25
EP3350215A1 (fr)	2018-07-25
US11407794B2 (en)	2022-08-09
US20180291069A1 (en)	2018-10-11
CN114591422A (zh)	2022-06-07
US11155586B2 (en)	2021-10-26
WO2017049009A8 (fr)	2018-02-22

Publication	Publication Date	Title
MA42036A (fr)	2018-03-14	Analogues nucléosidiques 5'-substitués
MA46180A (fr)	2021-03-24	Analogues de l'amyline
MA48596A (fr)	2021-03-31	Caractéristique d'inertie
FR3033706B3 (fr)	2017-04-21	Simulateur d'escalier
MA42771A (fr)	2018-07-18	Chaussure perméable à l'air
FR3033708B3 (fr)	2017-05-05	Simulateur d'escalier
MA42828A (fr)	2018-07-25	Plate-forme d'échafaudage à noeud de cystine
DK3512518T3 (da)	2023-01-30	Buprenophinformuleringer med langvarig frigivelse
JP1630897S (ja)	2019-05-13	手袋
IT201700090331A1 (it)	2019-02-08	"lopemide"
IT201700071679A1 (it)	2018-12-27	Remembebe'
MA51199A (fr)	2020-10-07	Agents d'imagerie
UA38213S (uk)	2018-12-26	Респіратор
UA37072S (uk)	2018-06-11	Респіратор протиаерозольний
UA34620S (uk)	2017-06-12	Іграшка - конструктор «мост»
IT201700103032A1 (it)	2019-03-14	Moschettone
ITUA20163709A1 (it)	2016-08-04	"presentosa3d"
FR3036257B3 (fr)	2017-07-28	"chaussure"
UA32431S (uk)	2016-06-24	Стрем'янка
FR3035837B1 (fr)	2017-04-14	Plaque d'immatriculation
ITUB201551290U1 (it)	2017-01-06	Ovie' oviel
UA34504S (uk)	2017-05-10	Упаковка для пальчаток «vitlux»
UA34505S (uk)	2017-05-10	Упаковка для пальчаток «vitlux»
UA34747S (uk)	2017-06-26	Кріпильний вузол
UA30584S (uk)	2015-10-12	Нитрилові рукавиці (4015190000)